Loading data for AQST — first visit, this takes a few seconds.
Aquestive Therapeutics, Inc. (AQST)
NasdaqGM: AQST
· Real-Time Price · USD
5.38
+0.14 (2.67%)
At close: Sep 03, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Aquestive Therapeutics, Inc. (AQST) Stock Price, Analysis & Data
No data available
| Bid | 2.67 |
| Market Cap | 671M |
| Revenue (ttm) | 54.1M |
| Net Income (ttm) | -78.2M |
| 1.43 | |
| -0.66 | |
| n/a | |
| -9.39 | |
| P/B (ttm) | -11.86 |
| P/S (ttm) | 12.41 |
| Earnings Date | Nov 4, 2026 |
| Ask | 4.78 |
| Volume | 1,810,788 |
| Avg. Volume (20D) | 2,669,788 |
| Open | 5.25 |
| Previous Close | 5.24 |
| Day's Range | 5.25 - 5.39 |
| 52-Week Range | 2.93 - 7.55 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AQST
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film ...
Sector Healthcare
IPO Date Jul 25, 2018
Employees 147
Stock Exchange NasdaqGM
Ticker Symbol AQST
Website https://www.aquestive.com
Financial Performance
In 2025, Aquestive Therapeutics's revenue was 44.55M, a decrease of -22.61% compared to the previous year's 57.56M. Earnings were -83.78M, an increase of 89.83%.
Financial StatementsEarnings Surprise
Aquestive Therapeutics has released their quarterly earnings on Aug 11, 2026:
- Revenue of $14.45M misses estimates by $0, with 65.67% YoY growth.
- EPS of -0.07 exceeds estimates by 0.05, with 41.67% YoY growth.
Aquestive Therapeutics, Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2